Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecut...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Med
Main Authors: Shrestha, Bikram, Sun, Yifei, Faisal, Farzana, Kim, Victoria, Soares, Kevin, Blair, Alex, Herman, Joseph M., Narang, Amol, Dholakia, Avani S., Rosati, Lauren, Hacker‐Prietz, Amy, Chen, Linda, Laheru, Daniel A., De Jesus‐Acosta, Ana, Le, Dung T., Donehower, Ross, Azad, Nilofar, Diaz, Luis A., Murphy, Adrian, Lee, Valerie, Fishman, Elliot K., Hruban, Ralph H., Liang, Tingbo, Cameron, John L., Makary, Martin, Weiss, Matthew J., Ahuja, Nita, He, Jin, Wolfgang, Christopher L., Huang, Chiung‐Yu, Zheng, Lei
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2017
נושאים:
Clinical Cancer Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504321/
https://ncbi.nlm.nih.gov/pubmed/28639410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1104
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים